DNA diagnostics based on mass spectrometry

• US 6,277,573 B1
• Filed: 04/06/1999
• Issued: 08/21/2001
• Est. Priority Date: 03/17/1995
• Status: Expired due to Term

• Current Assignee: Agena Bioscience Inc. (Mesa Laboratories Inc.)
• Original Assignee: Sequenom Incorporated (Laboratory Corporation Of America Holdings)
• Inventors: Köster, Hubert
• Primary Examiner(s): Horlick, Kenneth R.
• Application Number:
  US09/287,681
• Time in Patent Office: 868 Days
• Field of Search: 435/5, 435/6, 435/91.1, 435/91.2
• US Class Current: 435/5
• CPC Class Codes: C12Q 1/6816 characterised by the detection means C12Q1/6804 takes precedence
• CPC Class Codes: C12Q 1/6827 for detection of mutation or polymorphism
• CPC Class Codes: C12Q 1/6837 using probe arrays or probe chips C12Q1/6874 takes precedence
• CPC Class Codes: C12Q 1/6858 Allele-specific amplification
• CPC Class Codes: C12Q 1/686 Polymerase chain reaction [PCR]
• CPC Class Codes: C12Q 1/6862 Ligase chain reaction [LCR]
• CPC Class Codes: C12Q 1/6872 involving mass spectrometry
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 1/706 for hepatitis
• CPC Class Codes: C12Q 2521/325 Single stranded exonuclease
• CPC Class Codes: C12Q 2523/107 Chemical cleaving agents
• CPC Class Codes: C12Q 2523/319 Photocleavage, photolysis, photoactivation
• CPC Class Codes: C12Q 2525/107 incorporating a peptide nucleic acid
• CPC Class Codes: C12Q 2535/113 Cycle sequencing
• CPC Class Codes: C12Q 2535/125 Allele specific primer extension
• CPC Class Codes: C12Q 2535/131 Allele specific probes
• CPC Class Codes: C12Q 2537/113 Heteroduplex formation
• CPC Class Codes: C12Q 2565/625 being a nucleic acid test strip device, e.g. dipsticks, strips, tapes, CD plates
• CPC Class Codes: C12Q 2565/627 being a mass spectrometer
• CPC Class Codes: G01N 35/1067 for transfer to or from containers having different spacing
• CPC Class Codes: H01J 49/00 : Particle spectrometers or separator tubes
• CPC Class Codes: Y10T 436/143333 : Saccharide [e.g., DNA, etc.]
• CPC Class Codes: Y10T 436/24 : Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Abstract

Fast and highly accurate mass spectrometry-based processes for detecting particular nucleic acid molecules and sequences in the molecules are provided. Depending upon the sequence to be detected, the processes, for example, can be used to diagnose a genetic disease or a chromosomal abnormality, a predisposition to a disease or condition, or infection by a pathogen, or for determining identity or heredity.

Claims

1. A process for detecting the presence of a target nucleic acid sequence in a biological sample, comprising the steps of:

a) performing on a nucleic acid molecule comprising a target nucleic acid sequence, a first polymerase chain reaction comprising a first forward primer and a first reverse primer, which can amplify a portion of the nucleic acid molecule comprising at least a portion of the target nucleic acid sequence, thereby producing a first amplification product;

b) performing on the first amplification product, a second polymerase chain reaction comprising a second forward primer and a second reverse primer, which can amplify at least a portion of the first amplification product comprising at least a portion of the target nucleic acid sequence, thereby producing a second amplification product; and

c) detecting the amplification product by mass spectrometry, thereby detecting the presence of the target nucleic acid sequence in the biological sample.

2. A process of claim 1, wherein at least one primer selected from the group consisting of the first forward primer, the first reverse primer, the second forward primer, and the second reverse primer is an oligonucleotide mimetic.

3. A process of claim 2, wherein the oligonucleotide mimetic is a peptide nucleic acid.

4. A process of claim 1, wherein the amplification product is detected by contacting the amplification product with a detector oligonucleotide, which can hybridize specifically with the target nucleic acid sequence, and detecting a hybridized detector oligonucleotide by mass spectrometry, thereby detecting the amplification product.

5. A process of claim 4, wherein the detector oligonucleotide is an oligonucleotide mimetic.

6. A process of claim 1, wherein the nucleic acid molecule comprising the target nucleic acid sequence or an amplification product is immobilized on a solid support.

7. A process of claim 6, wherein the nucleic acid molecule or the amplification product is immobilized in an array on the solid support.

8. A process of claim 6, wherein the nucleic acid molecule or the amplification product is immobilized by hybridization to a capture nucleotide sequence, which is immobilized to the solid support and is complementary to a portion of the nucleic acid molecule or the amplification product.

9. A process of claim 8, wherein the capture nucleotide sequence comprises a primer selected from the group consisting of the first forward primer, the first reverse primer, the second forward primer, and the second reverse primer.

10. A process of claim 6, wherein the nucleic acid molecule or the amplification product is immobilized by direct bonding to the solid support.

11. A process of claim 6, wherein the solid support is selected from the group consisting of beads, flat surfaces, pins, combs and wafers.

12. A process of claim 1, wherein the nucleic acid molecule is one of a plurality of nucleic acid molecules, and wherein the nucleic acid molecules or the amplification products are immobilized by hybridization to an array of complementary capture nucleotide sequences, which are immobilized to a solid support.

13. A process of claim 12, wherein the complementary capture nucleotide sequences are oligonucleotide mimetics.

14. A process of claim 13, wherein the oligonucleotide mimetics are peptide nucleic acids.

15. A process of claim 6, wherein the immobilization is reversible.

16. A process of claim 6, wherein the immobilization is via a thiol linkage.

17. A process of claim 6, wherein the immobilization is via a photocleavable linkage.

18. A process of claim 1, wherein the mass spectrometry is selected from the group consisting of matrix-assisted laser desorption/ionization time-of-flight, electrospray, ion cyclotron resonance, Fourier transform, and combinations thereof.

19. A process of claim 1, further comprising conditioning the product to be detected by mass spectrometry.

20. A process of claim 19, wherein conditioning comprises introducing a mass modifying functionality in a base, sugar or phosphate moiety of the product.

21. A process of claim 19, wherein conditioning comprises exchanging cations at the phosphodiester bonds of the product.

22. A process of claim 1, wherein the nucleic acid molecule is obtained from an individual, and wherein detecting the target nucleic acid sequence provides a DNA fingerprint or is indicative of a disease or condition selected from the group consisting of a genetic disease, a chromosomal abnormality, a genetic predisposition, a viral infection, a fungal infection, a bacterial infection and a protist infection.

23. A process for detecting target nucleic acid sequences present in a plurality of nucleic acid molecules, comprising the steps of:

a) performing on nucleic acid molecules in the plurality, a first polymerase chain reaction comprising first primer pairs comprising a plurality of first forward primers and a plurality of first reverse primers, wherein a first primer pair can amplify a portion of a nucleic acid molecule comprising at least a portion of a target nucleic acid sequence, thereby producing first amplification products;

b) performing on the first amplification products, a second polymerase chain reaction comprising second primer pairs comprising a plurality of second forward primers and a plurality of second reverse primers, wherein a second primer pair can amplify at least a portion of a first amplification product comprising at least a portion of the target nucleic acid sequence, thereby producing second amplification products; and

c) detecting the amplification products by mass spectrometry, thereby detecting target nucleic acid sequences present in the plurality of nucleic acid molecules.

24. A process of claim 23, wherein at least one plurality of primers is selected from the group consisting of the first forward primers, the first reverse primers, the second forward primers, and the second reverse primers comprises oligonucleotide mimetic primers.

25. A process of claim 24, wherein the oligonucleotide mimetic primers are peptide nucleic acids.

26. A process of claim 23, wherein the amplification products are detected by contacting the amplification products with detector oligonucleotides, which can hybridize specifically with target nucleic acid sequences in the amplification products, and detecting hybridized detector oligonucleotides by mass spectrometry, thereby detecting the amplification products.

27. A process of claim 26, wherein the detector oligonucleotides are oligonucleotide mimetics.

28. A process of claim 23, wherein the nucleic acid molecules comprising the target nucleic acid sequences or the amplification products are immobilized on a solid support.

29. A process of claim 28, wherein the nucleic acid molecules or the amplification products are immobilized in an array on the solid support.

30. A process of claim 28, wherein the nucleic acid molecules or the amplification products are immobilized by hybridization to capture nucleotide sequences, each of which is immobilized to the solid support and is complementary to a portion of a nucleic acid molecule or an amplification product.

31. A process of claim 30, wherein each of the capture nucleotide sequences comprises a primer in the plurality selected from the group consisting of the first forward primers, the first reverse primers, the second forward primers, and the second reverse primers.

32. A process of claim 31, wherein the capture nucleotide sequences are oligonucleotide mimetics.

33. A process of claim 28, wherein the solid support is selected from the group consisting of beads, flat surfaces, pins, combs and wafers.

34. A process of claim 28, wherein the nucleic acid molecules or amplification products are immobilized via a bond that can be cleaved by a process selected from the group consisting of a chemical process, an enzymatic process and a physical process.

35. A process of claim 28, wherein the nucleic acid molecules or amplification products are immobilized via a bond that can be cleaved by a process selected from the group consisting of a chemical process, an enzymatic process and a physical process.

36. A process of claim 28, wherein the bond is a photocleavable bond.

37. A process of claim 23, wherein the mass spectrometry is selected from the group consisting of matrix-assisted laser desorption/ionization time-of-flight, electrospray, ion cyclotron resonance, Fourier transform, and combinations thereof.

38. A process of claim 23, further comprising conditioning the products to be detected by mass spectrometry.

39. A process of claim 23, wherein an amplification product representing a nucleic molecule in the plurality is distinguishable from each amplification product representing a different nucleic acid molecule in the plurality.

40. A process of claim 39, wherein the amplification products are mass differentiated and, thereby, distinguishable from each other.

41. A process of claim 40, wherein the amplification products are mass differentiated due to differences in length or sequence.

42. A process of claim 40, wherein the amplification products are mass differentiated due to the introduction of mass modifying functionalities in a base, sugar or phosphate moiety.

43. A process of claim 40, wherein the amplification products are mass differentiated due to an exchange of cations at the phosphodiester bonds.

44. A process of claim 23, wherein the nucleic acid molecules in the plurality are alleles of a gene.

45. A process of claim 23, wherein the nucleic acid molecules in the plurality are obtained from one or more individuals, and the target nucleotide provides a DNA fingerprint or is indicative of a disease or condition selected from the group consisting of a genetic disease, a chromosomal abnormality, a genetic predisposition, a viral infection, a fungal infection, a bacterial infection and a protist infection.